Lucas, Carrie L.
Chandra, Anita
Nejentsev, Sergey
Condliffe, Alison M.
Okkenhaug, Klaus
Article History
First Online: 12 September 2016
Change Date: 30 September 2016
Change Type: Corrigendum
Change Details: In Table 1 of the original version published online, the 'C416R' mutation was incorrectly referred to as 'C416K'. The authors and <i>Nature Reviews Immunology</i> apologise for this error. It has been corrected in the print and online versions of the article.
Competing interests
: C.L.L. collaborates with Novartis. A.C., S.N., A.M.C. and K.O. collaborate with and receive research funding from GlaxoSmithKline. K.O. has received consultancy or speaker fees from Karus Therapeutics, Merck, Gilead and Incyte.